Sumitomo Pharma Company Description
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally.
The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia.
It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs.
In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials.
Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish.
It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022.
The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
| Country | Japan |
| Founded | 1897 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4,980 |
| CEO | Toru Kimura |
Contact Details
Address: 6-8, Doshomachi 2-chome Osaka, 541-0045 Japan | |
| Phone | 81 6 6203 5321 |
| Website | sumitomo-pharma.com |
Stock Details
| Ticker Symbol | DNPUF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3495000006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Hiroshi Nomura | Chief Executive Officer, President and Representative Director |
| Toru Kimura Ph.D. | Senior Mngg Executive Off. of Glo. Crprate Stgy, F&A, Regen and Cell Med. Off., Kobe Ctr, Mfg. Plt and Dir. |
| Hiroyuki Baba | Mngg Executive Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, and Frontier Business Off. & Director |
| Naoki Noguchi | Executive Officer of Corporate Governance and Communications, Vice President and Head of Corporate Communications |
| Takuya Taguchi | M.E.O. of Sales and Marketing Div., SVice President, Hd of Sales & Marketing Div. and Dep. Hd of Japan Business Unit |
| Atsuko Higuchi | Managing Executive Officer of External Affairs, Corporate Secretariat and Human Resources |
| Yoshiharu Ikeda Ph.D. | Managing Executive Officer of Drug Research Division, Head of Japan Business Unit and Director |
| Koichi Kozuki | E.O. of R. Aff., Med. Sci., C.R.C. and Q.A., Senior Vice President, Hd of C.R.C. & Q.A. Div and Dp. Hd of Japan Business |
| Dr. Shigeyuki Nishinaka Ph.D. | Managing Executive Officer of Business Development and Management and Director |
| Isao Shimizu | Executive Officer, Senior Vice President, Head of Drug Research Division and Senior Executive Research Director |